Latest by Richard Jefferys
"As exemplified by the AZT protests, advocates have long pointed out the injustice of excessive, access-limiting profiteering on treatments developed with public support."
Results from the first human trials of a dual broadly neutralizing antibodies regimen appeared effective, safe, and well tolerated.
In the aftermath of the 22nd International AIDS Conference (AIDS 2018), there has been some reflecting on the challenges facing the HIV cure research field.
Invesitgators sought to determine whether human liver macrophages can sequester infectious HIV in people on antiretroviral therapy.
Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.
The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T-cell counts in the absence of antiretroviral therapy has led them to be proposed as a model for a functional cure of HIV infection.
During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...
There is growing interest in cells considered part of the innate immune system, particularly natural killer (NK) cells. A number of studies have been published that support the idea that NK cells can play an important role in controlling virus replic...
Several recently presented and published studies offer potentially important new data relevant to efforts to identify cells containing latent HIV and target them for elimination.